Journal of the National Cancer Center最新文献

{"title":"Meningeal immune convergence: IFN-γ–driven DC–NK axis suppresses leptomeningeal tumor","authors":"Yicheng Zhi , Chenyang Ye , Yi Sun , Ji Wang","doi":"10.1016/j.jncc.2026.02.001","DOIUrl":"10.1016/j.jncc.2026.02.001","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 2","pages":"Pages 117-119"},"PeriodicalIF":9.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A global review and perspective on prostate cancer survival: findings from survival studies of cancer registration data","authors":"Yuxin Zhou ,&nbsp;Yixin Zou ,&nbsp;Qiuming Shen ,&nbsp;Zhuoying Li ,&nbsp;Yuting Tan ,&nbsp;Honglan Li ,&nbsp;Yongbing Xiang","doi":"10.1016/j.jncc.2026.01.005","DOIUrl":"10.1016/j.jncc.2026.01.005","url":null,"abstract":"<div><h3>Background</h3><div>To better understand global status, temporal trends, and geographic disparities of prostate cancer survival, we systematically collected published survival studies on prostate cancer from cancer registries worldwide.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted in databases such as PubMed, Embase, Web of Science, SinoMed, CNKI and SEER for survival studies from cancer registries up to April 30, 2025. We synthesized data on observed, relative and net survival since the 1990s, along with age-standardized survival, and further stratified based on age at diagnosis and stage.</div></div><div><h3>Results</h3><div>The overall survival was favorable and exhibited a continuous improving trend. In most countries and regions, the 5-year relative survival rate exceeded 70%. However, substantial geographic disparities were observed. The prognosis was better in developed countries in Europe and America than that in less developed countries in Asia and Africa. Since 2000, the age-standardized 5-year relative survival was the highest in the United States at 98.5% (2007–2010), while it was the lowest in Punjab of India at 30.3% (2013–2016). The prognosis was poorest for patients aged ≥ 75, or for those diagnosed with distant or stage IV.</div></div><div><h3>Conclusions</h3><div>Although the survival has been improving over the past three decades, disparities between developed and less developed countries still persist. The extent of the popularization of prostate screening programs, the age or stage at diagnosis, and the sophistication of healthcare systems are likely to be significant contributing factors to these differences. Our results can provide fundamental statistics for formulating and refining relevant policies.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 2","pages":"Pages 175-184"},"PeriodicalIF":9.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147652793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering vascular invasion terminology in hepatocellular carcinoma staging: implications for accurate prognosis and treatment","authors":"Qing-Bo Wang ,&nbsp;Wan-Ling Luo ,&nbsp;Zi-Sheng Yang ,&nbsp;Hao-Bo Xu ,&nbsp;Jin-Yi Zhou ,&nbsp;Yue Yu ,&nbsp;Jian-Biao Zhang ,&nbsp;Yang Ke","doi":"10.1016/j.jncc.2026.01.003","DOIUrl":"10.1016/j.jncc.2026.01.003","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 2","pages":"Pages 120-121"},"PeriodicalIF":9.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the genetic overlap between obstructive sleep apnea and prostate cancer","authors":"Allan Saj Porcacchia ,&nbsp;Mariana Moyses-Oliveira ,&nbsp;Gabriel Natan Pires ,&nbsp;Monica Levy Andersen ,&nbsp;Sergio Tufik","doi":"10.1016/j.jncc.2025.11.004","DOIUrl":"10.1016/j.jncc.2025.11.004","url":null,"abstract":"<div><h3>Background</h3><div>Studies have highlighted the possible association between obstructive sleep apnea (OSA) and an increased risk of cancer, especially prostate cancer. However, the extent to which genes that are found in both conditions contribute to their comorbidity is unclear. The aim of this study was to identify risk genes present in both conditions.</div></div><div><h3>Methods</h3><div>Genes common to both conditions were identified and the statistical significance of the overlap was assessed. Pathway enrichment and protein–protein interaction analyses were performed on the intersecting gene set.</div></div><div><h3>Results</h3><div>There were 68 common genes, more than would be expected by random effects. This intersect list was associated mainly with hypoxia, apoptosis, oxidative stress, and cell cycle proliferation, or cell damage. A 17-node protein interaction network highlighted key proteins involved in these enriched pathways.</div></div><div><h3>Conclusions</h3><div>The results of the analysis indicated a common molecular etiology underlying this comorbidity. Proliferation, apoptosis, and hypoxia pathways were significantly enriched among the overlapping genes, suggesting their role in pathophysiological processes.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 2","pages":"Pages 204-210"},"PeriodicalIF":9.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147652783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential survival impact of acetaminophen and non-steroidal anti-inflammatory drugs on NSCLC patients undergoing immune checkpoint inhibitor therapy: a region-wide cohort study in Hong Kong, China","authors":"Si-Chao Wang ,&nbsp;Zheng-Hao Ye ,&nbsp;Han Zhou ,&nbsp;Ze-Rui Zhao ,&nbsp;Yu-Heng Zhou ,&nbsp;Shu-Jie Huang ,&nbsp;Zhen Gao ,&nbsp;Zi-Hao Zhou ,&nbsp;Dan-Yang Zheng ,&nbsp;Yin-Nan Meng ,&nbsp;Teddy Tai Loy Lee ,&nbsp;Abraham Ka Chung Wai ,&nbsp;Feng-Ming (Spring) Kong","doi":"10.1016/j.jncc.2026.02.003","DOIUrl":"10.1016/j.jncc.2026.02.003","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 2","pages":"Pages 185-188"},"PeriodicalIF":9.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147652785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adaptive therapy: a balanced triangle for chronic cancer management","authors":"Wenhui Guan ,&nbsp;Yilin Yang ,&nbsp;Chengzhi Zhou","doi":"10.1016/j.jncc.2026.01.006","DOIUrl":"10.1016/j.jncc.2026.01.006","url":null,"abstract":"<div><div>The increasing complexity of cancer treatment, which requires balancing curative-intent therapy, long-term disease control with treatment-related adverse events (TRAEs), underscores the need for a dynamic approach. We propose an expanded definition of modern adaptive therapy in oncology, which focuses on balancing tumor burden, therapeutic efficacy, and TRAEs to optimize outcomes across the entire cancer care continuum, from curative-intent treatment to long-term disease management. This approach is enabled by biomarker-guided patient selection, dynamic tumor burden assessment, and longitudinal monitoring of treatment response and treatment-related adverse events. Within this framework, treatment intensity is modulated through escalation, de-escalation, or intermittent (“holiday”) strategies, supported by advanced imaging, liquid biopsy, and emerging artificial intelligence tools for real-time disease assessment. By integrating these principles, modern adaptive therapy aims to maximize clinical benefit while minimizing avoidable toxicity, enhancing quality of life, improving survival, and promoting more sustainable and cost-effective cancer care.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 2","pages":"Pages 125-129"},"PeriodicalIF":9.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147652787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Catching pancreatic cancer early: Are we there yet?","authors":"Aminath Rana Abdul Rasheed ,&nbsp;Rhun Yian Koh ,&nbsp;Wei-Meng Lim ,&nbsp;Chun-Wai Mai ,&nbsp;Chin-King Looi","doi":"10.1016/j.jncc.2025.12.001","DOIUrl":"10.1016/j.jncc.2025.12.001","url":null,"abstract":"<div><div>Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies worldwide, primarily due to its aggressive nature and the predominance of late-stage diagnoses. The 5-year survival rate remains dismal, often below 7 %, underscoring the urgent need for effective early detection strategies. Despite advancements in imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasound (EUS), population-wide screening remains impractical due to the disease’s low incidence and lack of specific early biomarkers. Recent technological innovations, including artificial intelligence (AI)-driven imaging analysis and the discovery of circulating biomarkers have shown promising potential in improving early diagnosis and risk stratification. AI-enabled pancreas segmentation and radiomics further enhance the detection of subtle morphological changes that may be imperceptible to human naked eyes. However, these approaches remain largely investigational and require further validation, standardization, and clinical integration. This review summarizes current advances and ongoing challenges in early PDAC detection, emphasizing that despite promising developments, clinically effective early detection strategies are still lacking. Continued efforts to integrate multi-omics profiling, refine imaging technologies, and incorporate AI-assisted diagnostics into validated, risk-based screening models are essential to move toward earlier intervention and improved patient outcomes.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 2","pages":"Pages 130-148"},"PeriodicalIF":9.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147652788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T cell-intrinsic integrated stress response: friend, foe, or frill?","authors":"Si Lu ,&nbsp;Chenghang Zhao ,&nbsp;Yuxiong Feng","doi":"10.1016/j.jncc.2026.03.001","DOIUrl":"10.1016/j.jncc.2026.03.001","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 2","pages":"Pages 122-124"},"PeriodicalIF":9.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of circadian disruption, sleep dysregulation, lifestyle factors, and metabolic reprogramming in the pathogenesis and progression of ovarian cancer","authors":"Malvi Surti ,&nbsp;Anjali Gupta ,&nbsp;Komal Janiyani ,&nbsp;Mohd Adnan ,&nbsp;Mitesh Patel","doi":"10.1016/j.jncc.2026.01.009","DOIUrl":"10.1016/j.jncc.2026.01.009","url":null,"abstract":"<div><div>Ovarian cancer remains one of the most lethal gynecologic malignancies, with high mortality due to late-stage diagnosis and limited effective treatments. Recent evidence highlights the importance of circadian rhythms, metabolic reprogramming, and lifestyle factors in shaping the initiation, progression, and treatment response of ovarian tumors. Disruption of the circadian clock, via genetic dysregulation or lifestyle behaviors such as night-shift work and poor sleep, has been associated with tumorigenesis, metabolic imbalance, and chemoresistance. Additionally, ovarian cancer cells demonstrate distinct metabolic adaptations, including enhanced glycolysis and glutaminolysis, supporting rapid proliferation and survival. Lifestyle factors such as diet, physical inactivity, obesity, and psychosocial stress further modulate cancer risk and therapeutic outcomes. This review synthesizes evidence on the molecular underpinnings of circadian and metabolic disruption in ovarian cancer and their interaction with modifiable behavioral factors. Furthermore, it explores emerging strategies such as chronotherapy and metabolic targeting to improve treatment efficacy and survivorship. The goal is to encourage a multidimensional perspective that integrates molecular biology with lifestyle medicine in the management of ovarian cancer.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 2","pages":"Pages 189-203"},"PeriodicalIF":9.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147652784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The global burden of early-onset cancer in women, 1990–2021: findings from the GBD 2021 with focus on China","authors":"Yibei Li ,&nbsp;Danqi Huang ,&nbsp;Jingyi Liu ,&nbsp;Yang Bai ,&nbsp;Bobo Zheng ,&nbsp;Quan Wang ,&nbsp;Wenbo Meng ,&nbsp;Jinqiu Yuan ,&nbsp;Min Yang ,&nbsp;Jingbo Zhai ,&nbsp;Jiang Li","doi":"10.1016/j.jncc.2026.01.002","DOIUrl":"10.1016/j.jncc.2026.01.002","url":null,"abstract":"<div><h3>Background</h3><div>Early-onset cancer is a significant public health threat in females, yet comprehensive data on its global burden and temporal trends remain limited. Our study aimed to provide a comprehensive assessment of global burden of female early-onset cancer from 1990 to 2021, and to project its change to 2050.</div></div><div><h3>Methods</h3><div>This study analyzed the incidence, mortality, and disability-adjusted life years (DALYs) of female early-onset cancers (ages 15–49 years) from 1990 to 2021, with projections to 2050, using Global Burden of Disease (GBD) 2021 data. We presented absolute counts and age-standardized rates (ASRs) per 100,000 population for 31 malignancies with 95% uncertainty intervals (UIs). Estimated annual percentage changes (EAPCs) quantified temporal trends in ASRs, while Autoregressive Integrated Moving Average (ARIMA) models projected future burden. Countries were stratified by socio-demographic index (SDI) quintiles, and Spearman rank correlation analysis and Frontier analysis were used to explore the relationship between SDI and disease burden. Risk-attributable burden was assessed through GBD’s comparative risk framework.</div></div><div><h3>Results</h3><div>From 1990 to 2021, the number of global new cases of female early-onset cancers rose from 11.49 to 17.06 million, and the number of deaths increased from 0.40 million to 0.51 million. Early-onset breast cancer had the highest burden, followed by cervical cancer. Globally, the age-standardized incidence rate (ASIR) showed a slight decline with the EAPC of -0.13%, whereas the United States saw a significant rise (EAPC = 1.36%). The age-standardized mortality rate (ASMR) declined significantly (EAPC = -1.14%), with China experiencing a steep reduction (EAPC = -2.09%). Modifiable risk factors accounted for 31.44% of total deaths in 2021, concentrated in cervical (100% of its deaths attributable to modifiable risk factors), lung (50.05%), and colorectal cancers (50.85%). Projections indicated that ASIR would peak at 880.95 per 100,000 by 2027 and subsequently stabilize, while ASMR would decline to 23.74 per 100,000 by 2050.</div></div><div><h3>Conclusions</h3><div>The findings of this study characterize the global disease burden of early-onset cancers in women, encompassing temporal trends, regional disparities, risk attribution, and future projections, further validating the significance of preventive strategies including screening. Our results provide insights for targeted preventive strategies of early-onset cancers for female populations.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 2","pages":"Pages 149-158"},"PeriodicalIF":9.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147652786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}